Zydus Cadila today said it has received USFDA approval to market Triamterene and Hydrochlorothiazide tablets, indicated to treat high blood pressure. The approval has been granted for the tablets in strengths of 37.5 mg/25 mg and 75 mg/50 mg.
Subscribe to:
Post Comments (Atom)
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
-
In July, HCL Technologies had announced a Rs 4,000 crore buyback programme for FY19 at a price of Rs 1,100 per equity share.
No comments:
Post a Comment